Aprotinin: Pharmacological benefits and safety concerns

Andrea Székely, Daniel J. Lex, B. Merkely

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)


In cardiac surgery, perioperative blood transfusion carries considerable risk of complications and increases resource utilization. Antifibrinolytics, particularly aprotinin, have been used effectively to reduce bleeding and transfusion needs. In 2008, the manufacturer withdrew aprotinin from the market due to the discontinued “Blood conservation using antifibrinolytics in a Randomized Trial” (Brat) study, which showed an increased mortality associated with the use of aprotinin.

Original languageEnglish
Title of host publicationReducing Mortality in the Perioperative Period
PublisherSpringer International Publishing
Number of pages6
ISBN (Print)9783319021867, 9783319021850
Publication statusPublished - Jan 1 2014


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Székely, A., Lex, D. J., & Merkely, B. (2014). Aprotinin: Pharmacological benefits and safety concerns. In Reducing Mortality in the Perioperative Period (pp. 125-130). Springer International Publishing. https://doi.org/10.1007/978-3-319-02186-7_16